< Key Hightlight >

MARKET OUTLOOK

The global non-PVC IV bags market is expected to develop with a CAGR of 7.32% in the forecasting years from 2021 to 2028.

The primary factor driving the growth of this market is the rising demand for parenteral nutrition in newborns. Moreover, the high prevalence of chronic conditions is another factor contributing to market growth. On the other hand, the high cost of non-PVC IV bags, along with the stringent rules imposed by regulatory bodies, are hindering the market growth process. However, these days, non-PVC IV bags are being used to prevent hazardous chemical effects. This indicates an overall positive outlook for the market studied.

REGIONAL OUTLOOK

Latin America, Europe, the Middle East and Africa, the Asia-Pacific, and North America together shape the global market for non-PVC IV bags. 

North America holds the largest share of the market and is expected to showcase steady growth during the forecasted period. Countries in the region have a well-defined regulatory framework, which contributes to the adoption of non-PVC IV bags. Also, the growth here is a result of the high prevalence rate of diseases and favorable reimbursement policies.

COMPETITIVE OUTLOOK

Some of the major players engaged in the non-PVC IV bags market include Huaren Pharmaceutical, Otsuka, Kraton Corporation, Angiplast Pvt Ltd, Polycine GmbH, Renolit, Fresenius Kabi, Baxter International Inc, Medipharmaplan, Pfizer Inc, B Braun Melsungen AG, Shanghai Xin Gen Eco Technologies, JW Life Science,Sealed Air, and ICU Medical.

Baxter International Inc is a globally renowned healthcare company offering sterile intravenous (IV) solutions, acute & chronic dialysis therapies, infusion systems & devices, generic injectable pharmaceuticals, parenteral nutrition therapies, inhaled aesthetics, and surgical hemostat & sealant products. It sells its IV bags under the brand name VIAFLEX. 

It also offers frozen and liquid premix systems of non-PVC IV bags containing a range of injections. The company was founded in 1931. Baxter has operations across North America, the Middle East and Africa, Europe, and the Asia-Pacific. The company manufactures its products in 20 countries and markets them in over 100 countries. It conducts R&D activities to remain competitive in the market through product development.